AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On March 16, 2017, the Company posted to its website a
“Corporate Presentation” containing certain information that
management may use during various presentations to enhance an
understanding of the Company’s business and operations. A copy
of this “Corporate Presentation” is attached hereto as Exhibit
99.1.
“Corporate Presentation” containing certain information that
management may use during various presentations to enhance an
understanding of the Company’s business and operations. A copy
of this “Corporate Presentation” is attached hereto as Exhibit
99.1.
The information responsive to this Item 7.01 of this Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for
purposes of Section 18 of the Exchange Act or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
or the Exchange Act, except as may be expressly set forth by
specific reference in such a filing.
including Exhibit 99.1, shall not be deemed “filed” for
purposes of Section 18 of the Exchange Act or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
or the Exchange Act, except as may be expressly set forth by
specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
99.1
|
Avadel Pharmaceuticals plc Corporate Presentation
|
AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Recent Trading Information
AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) closed its last trading session up +0.01 at 10.12 with 47,903 shares trading hands.
